An Open Label, Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Checkpoint Inhibitor Treatment naïve Adults With Unresectable or Metastatic Melanoma
Latest Information Update: 19 Jul 2024
At a glance
- Drugs EVX 01 (Primary) ; Pembrolizumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Sponsors Evaxion Biotech
- 16 Jul 2024 According to an Evaxion Biotech media release, the details of this trial was discussed in AI-Immunology platform, at the 32nd Intelligent Systems for Molecular Biology (ISMB) conference taking place in Montreal, Canada, from July 12-16, 2024.
- 04 Jun 2024 Results presented at the 60th Annual Meeting of the American Society of Clinical Oncology
- 03 Jun 2024 Results published in an Evaxion Biotech Media Release.